Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Significance of Tuberculin Testing in HIV Infection: An Indian Perspective.

Sawhney M, Sharma YK.

Med J Armed Forces India. 2006 Apr;62(2):104-7. doi: 10.1016/S0377-1237(06)80047-X. Epub 2011 Jul 21.

3.

Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain.

Diaz A, Diez M, Bleda MJ, Aldamiz M, Camafort M, Camino X, Cepeda C, Costa A, Ferrero O, Geijo P, Iribarren JA, Moreno S, Moreno ME, Labarga P, Pinilla J, Portu J, Pulido F, Rosa C, SantamarĂ­a JM, Telenti M, Trapiella L, Trastoy M, Viciana P.

BMC Infect Dis. 2010 Sep 14;10:267. doi: 10.1186/1471-2334-10-267.

4.

Tuberculosis and illicit drug use: review and update.

Deiss RG, Rodwell TC, Garfein RS.

Clin Infect Dis. 2009 Jan 1;48(1):72-82. doi: 10.1086/594126. Review.

5.

Hepatitis C management by addiction medicine physicians: results from a national survey.

Litwin AH, Kunins HV, Berg KM, Federman AD, Heavner KK, Gourevitch MN, Arnsten JH.

J Subst Abuse Treat. 2007 Jul;33(1):99-105. Epub 2007 Mar 26.

6.

Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis.

Sadaphal P, Astemborski J, Graham NM, Sheely L, Bonds M, Madison A, Vlahov D, Thomas DL, Sterling TR.

Clin Infect Dis. 2001 Nov 15;33(10):1687-91. Epub 2001 Oct 12.

7.

Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program.

Perlman DC, Gourevitch MN, Trinh C, Salomon N, Horn L, Des Jarlais DC.

J Urban Health. 2001 Sep;78(3):550-67.

8.

Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A.

Desta Z, Soukhova NV, Flockhart DA.

Antimicrob Agents Chemother. 2001 Feb;45(2):382-92.

Supplemental Content

Support Center